Beijing Coyote Bioscience Co., Ltd. (北京卡尤迪生物科技股份有限公司) - Pioneer in POCT Molecular Diagnostics

Company Profile (Updated April 2026)

Beijing Coyote Bioscience Co., Ltd. (北京卡尤迪生物科技股份有限公司) is a national high-tech enterprise dedicated to the research, development, production, and sales of portAble gene molecular diagnostic systems. Founded on December 4, 2009 in Beijing, china, the company is headquartered in Building 22, Yard 3, Cloud Center, Zhongguancun Cuihu Science and Technology Park, HAidian District, Beijing.

The company is committed to simplifying complex nucleic acid testing experiments into easy-to-use, point-of-care solutions. Its molecular diagnostic systems are widely used in life science research, clinical diagnostics, food safety, public health emergency response, and customs quarantine. The company's vision is "Let everyone benefit from molecular diagnostics" (让每一个人都受益于分子诊断).

Core Mission: To make molecular diagnostics faster, simpler, and more accessible through original cross-disciplinary innovation, enabling Rapid nucleic acid detection at the point of care without requiring professional laboratories or operators.

Founder and Leadership

Founder / Chairman / CEO: Li Xiang (李响)

- Graduated from Peking University with a bACHelor's degree in Physics

- Earned a master's degree in Biophysics from the University of California, USA

- Returned to China in 2006 as one of the first overseas returnees in synthetic biology entrepreneurship

- Recognized as a "Beijing Overseas High-Level Talent", "Beijing Specially Appointed Expert", "Top Ten Zhongguancun Returnee New Stars", and an outstanding representative of the "Haiju Program" (Sea-Gathering Program) among the post-80s generation

- Awarded "2022 Product Manager of the Year" by the Hot Intestine Award (热心肠奖)

COO: Angela Zhang — PhD in Biomedical Sciences from Stanford University, former VP at SAIF Partners

CTO: Jesus Ching — Former R&D Director at Cepheid, the first US company in point-of-care molecular diagnostics

Core R&D Team: Graduates from UCSD, Peking University, Tsinghua University, Beijing Institute of Technology, China Agricultural University, and other top institutions

Financing History

Series A (2014): RMB 30 million, led by SAIF Partners (赛富亚洲)

Series B (2015): RMB 80 million, led by Northern Light Venture Capital (北极光创投), with participation from SAIF Partners and Legend Star (联想之星)

Series C: Participating investors Included Longpan Capital (龙磐资本) and Chang'an Capital (长安资本)

Series D (December 2020): Nearly RMB 600 million, led by Hillhouse Venture Capital (高瓴创投), with strategic investment from GenHe Capital (金阖资本) and follow-on investment from Huiyuan Capital (惠远资本) and FreesFund (峰瑞资本)

Medical Laboratory Spin-off Financing: RMB tens of millions, jointly invested by FreesFund and Lianli Capital

Total Funding Raised: Nearly RMB 600 million (approximately $35 million+ in early-stage USD financing)

Strategic Investment: KingMed Diagnostics (金域医学) invested in Coyote Bioscience as part of its digital PCR strategic layout

Global Operations and Subsidiaries

Headquarters / R&D Center (Beijing): Zhongguancun Cuihu Science and Technology Park, Haidian District, Beijing — Focus on instrument R&D and core technology development

GMP Production Base (Yixing, jiangsu): Coyote Bioscience Yixing Co., Ltd. — Wholly-owned subsidiary located in Yixing Economic Development Zone, covering 7,000-8,000 sqm, dedicated to instrument manufacturing and reagent production

Medical Testing Laboratory (Beijing Changping): Coyote Medical Laboratory (Beijing) Co., Ltd. — Established in 2015 and operational since August 2016, located in Peking University Medical Industry Park, Zhongguancun Life Science Park. Covers approximately 2,000 sqm including 1,200 sqm Class 200,000 clean laboratory. Provides third-party testing services including infectious disease screening, microbiome analysis, cancer screening, and genetic diagnosis

US R&D Center (San Francisco / Columbia, MD): Coyote Bioscience USA — Established in 2015, covering approximately 1,500 sqm. Focuses on frontier product research and US market sales and marketing. Address: 9625 Pastora Place, Columbia, MD 21045, USA

Core Technology and Product Portfolio

FlashTest™ (闪测™) Molecular POCT Platform

The company's flagship product line covers molecular detection from large central laboratories to medical institution emergency departments, to primary healthcare institutions:

- FlashTest™ Flash10: Daily throughput 200+ samples, suitable for medium-sized laboratories

- FlashTest™ Flash20: Approved by NMPA as Class III medical device in July 2020. Achieves 1-minute sample loADINg, 30-minute results — the fastest PCR platform globally at the time of launch

- FlashTest™ Robo: Daily throughput 1,800+ samples. Automated nucleic acid testing robot requiring no professional operators or laboratories — sample-in, result-out

- FlashTest™ Nano (Launched August 2024): Molecular POCT robot integrating AI artificial intelligence. Dimensions 12.5×22×29.8 cm, weight 4 kg. Results in as fast as 8 minutes. Features integrated microfluidic cartridge, pre-loaded reagents, one-button operation, intelligent result interpretation, and automatic report uploading. Sensitivity: 100-500 copies/mL. Supports Nano Matrix multi-device chaining for flexible throughput expansion. Covers respiratory, digestive, reproductive, blood infectious diseases, personalized medication, and oncology testing

Digital PCR Solutions

- DX-100 Droplet Digital PCR System: Includes droplet generator, real-time fluorescence quantitative PCR instrument, and biochip analyzer. Enables absolute quantification with high sensitivity, precision, and tolerance for trace targets and low-frequency mutation detection

Instruments and Reagents

- Instruments: Constant temperature metal bath, tissue grinder, gene amplifier, fluorescence quantitative PCR instrument — covering temperature control, photoelectric, and electromechanical integration technologies

- Reagent Applications: Nucleic acid extraction, nucleic acid amplification, nucleic acid detection

- Testing Menus: Respiratory pathogens, digestive pathogens, reproductive tract infections, blood infectious diseases, personalized medication, tumor markers, microbial communities (gut microbiome, reproductive tract microbiome), cancer screening, and genetic diagnosis

2025-2026 Latest Developments

National Major Science and Technology Project (April 2026)

On April 2, 2026, the company held the launch meeting of a national major science and technology project in Beijing. The project focuses on national "15th Five-Year Plan" major needs and tackles "ultra-fast, ultra-sensitive" molecular POCT frontiers, consolidating the company's leadership in rapid molecular diagnostics innovation.

Tuberculosis Prevention and Control (March 2026)

In March 2026, the company's tongue swab innovation technology for tuberculosis (TB) screening received high attention at industry conferences, offering a new non-invasive sampling path for TB prevention and control.

CACLP 2026 Exhibition (March 2026)

In March 2026, the company exhibited at the CACLP (China Association of Clinical Laboratory Practice Expo), showcasing its latest molecular POCT innovations and continuing to write a new chapter in the POCT field.

Nipah Virus Emergency Response (January 2026)

In January 2026, as global health authorities raised alerts for the Nipah virus, the company's FlashTest™ 30-minute molecular POCT platform was positioned to guard the first line of defense against the outbreak, demonstrating rapid deployment capability for emerging infectious diseases.

Global Distributors Conference (February 2026)

In February 2026, the company held its 2026 Global Distributors Conference in Dubai, strengthening international partnerships and expanding global market presence under the theme "Connecting with the World."

Key Laboratory Advancement (February 2026)

In February 2026, the company's three key laboratories embarked on new journeys, supporting continued R&D breakthroughs in molecular diagnostics.

Certifications, Honors, and Intellectual Property

- National High-Tech Enterprise

- Zhongguancun High-Tech Enterprise

- "Haiju Program" (Sea-Gathering Program) Enterprise

- 2013: Awarded "Most Growth-Potential Overseas Returnee Startup in China"

- Zhongguancun "Golden Seed Project" Enterprise

- ISO 9001 Quality Management System Certification

- CE Certification for product export to Europe

- WHO Recommended: Ebola virus "one-step" nucleic acid diagnostic reagent listed in WHO recommendation list

- Military Supply: Provided Ebola virus diagnostic reagents to the military

- Export Markets: Products exported to 30+ countries and regions including the United States, Japan, South Korea, Europe, India, and Southeast Asia

- Patents: 83 patents applied for, including 13 Chinese patents, 2 US patents, 1 Australian patent, and 22 PCT international patents

- National Projects: Undertook the National Major Science and Technology Project for Key Infectious Diseases and the Ministry of Science and Technology Torch Program Project

- 2019: Led the first AIDS rapid one-hour on-site testing platform project under the national infectious disease major project

- COVID-19: Ranked among the top 7 companies in China for novel coronavirus IVD reagent registrations (2020-2025), with 4 registered products

Company Basic Information

Corporate Overview

Company Full Name: Beijing Coyote Bioscience Co., Ltd. (北京卡尤迪生物科技股份有限公司)

Founded: December 4, 2009

Legal Representative / Founder / Chairman / CEO: Li Xiang (李响)

Registered Address: Room D1301, No. 29 Bishan Street, Haidian District, Beijing, China (also listed as Building 22, Yard 3, Cloud Center, Zhongguancun Cuihu Science and Technology Park, Haidian District, Beijing)

Office Address: Building 22, Yard 3, Cloud Center, Zhongguancun Cuihu Science and Technology Park, Haidian District, Beijing, China

Company Type: Joint-Stock Limited Company (Non-Listed)

Industry: Medical Devices / In Vitro Diagnostics (IVD) / Molecular Diagnostics / POCT

Registered Capital: RMB 70,221,446 (70.22 million)

Employees: Approximately 100-499 (current recruitment data); historically 150+

Official Website: www.coyotebio.com

Email: wmbio@coyotebio.com (reference)

Subsidiaries and Affiliates

- Coyote Bioscience Yixing Co., Ltd. (卡尤迪生物科技宜兴有限公司) — Wholly-owned subsidiary, GMP production base in Yixing, Jiangsu

- Coyote Medical Laboratory (Beijing) Co., Ltd. (卡尤迪医学检验实验室（北京）有限公司) — Wholly-owned subsidiary, third-party medical testing laboratory in Changping, Beijing

- Coyote Bioscience USA — US subsidiary established in 2015, R&D center and US market sales, San Francisco / Columbia, MD

Market Presence and Competitive Landscape

Domestic Market

- Products introduced to 1,000+ Class III (tertiary) hospitals nationwide by 2021

- Rapid nucleic acid testing platforms deployed in government large-scale screening scenarios during the COVID-19 pandemic

- Molecular POCT solutions applied in primary healthcare institutions, emergency departments, and grassroots medical facilities

International Market

- Products exported to 30+ countries and regions

- WHO-recommended Ebola diagnostic reagents supplied to international markets and military users

- US R&D center collaborating with top American research institutions

- Global distributor network expanded through the 2026 Dubai Global Distributors Conference

Competitive Position

Coyote Bioscience is recognized as one of the leading global POCT molecular diagnostics companies. It is frequently cited alongside Danaher (Cepheid), Roche, Abbott, bioMérieux, Hologic, Thermo Fisher, and domestic peers such as Ustar in industry reports on the global POCT molecular diagnostics market. The company holds original platform technology with global patent protection and is one of the few domestic companies with true sample-in, result-out molecular POCT capabilities.

2026 Outlook and Strategic Priorities

Strategic Focus Areas

- National Major Project Execution: Advance the "ultra-fast, ultra-sensitive" molecular POCT national science and technology project under the 15th Five-Year Plan

- Product Innovation: Continue developing the FlashTest™ platform with richer pathogen detection menus, including respiratory, digestive, reproductive, and blood infectious diseases

- AI Integration: Leverage AI-powered intelligent result interpretation and automated report generation in the Nano platform

- Tuberculosis and Emerging Diseases: Expand tongue swab TB screening and rapid response capabilities for emerging infectious diseases such as Nipah virus

- Microbiome and Precision Medicine: Develop gut microbiome, reproductive tract microbiome, cancer screening, and genetic diagnosis product lines

- International Expansion: Strengthen global distributor networks and US market presence through the San Francisco R&D center

- Primary Healthcare Penetration: Accelerate deployment of molecular POCT solutions to grassroots medical institutions and support China's hierarchical medical system

Competitive Advantages

- Original Innovation: Global patent-protected platform technology developed through cross-disciplinary innovation (physics, biophysics, synthetic biology, microfluidics)

- Speed Leadership: FlashTest™ Flash20 was the world's fastest PCR platform at launch (30 minutes); Nano further reduces this to 8 minutes for certain assays

- True POCT: Sample-in, result-out capability without professional laboratories or operators

- Product Breadth: Full coverage from large central labs (Robo) to emergency departments (Flash10/20) to primary care and field settings (Nano)

- Strong Investor Backing: Support from top-tier investors including Hillhouse, Northern Light, SAIF Partners, Legend Star, and GenHe Capital

- National Project Leadership: Repeated selection for national major science and technology projects, demonstrating government recognition of technical leadership

Contact Information

Headquarters

Address: Building 22, Yard 3, Cloud Center, Zhongguancun Cuihu Science and Technology Park, Haidian District, Beijing, China
   Website: www.coyotebio.com

Production Base

Address: Yixing Economic Development Zone, Jiangsu, China (Coyote Bioscience Yixing Co., Ltd.)

Medical Laboratory

Address: 2nd Floor, Building 14, Peking University Medical Industry Park, Zhongguancun Life Science Park, Changping District, Beijing, China (Coyote Medical Laboratory)

US Office

Address: 9625 Pastora Place, Columbia, MD 21045, USA

Keywords: Beijing Coyote Bioscience,CoyoteBio,卡尤迪,POCT,Molecular Diagnostics,Nucleic Acid Detection,FlashTest,闪测,Li Xiang,李响,PCR,Digital PCR,DX-100,Flash10,Flash20,Flash Robo,Flash Nano,Ebola,Zika,Tuberculosis,Nipah Virus,Gut Microbiome,Microbiome,Precision Medicine,National High-Tech Enterprise,Zhongguancun,Haiju Program,Hillhouse Venture Capital,Northern Light Venture Capital,SAIF Partners,Legend Star,GenHe Capital,Yixing,Beijing,China